Filing Flows › AbCellera Biologics (ABCL) › Research fees revenue
AbCellera Biologics (ABCL) Research fees revenue by quarter
AbCellera Biologics' Research fees revenue was $3.9M in Q2 2026 (second quarter 2026), -52% from Q1 2026. Over the last 7 quarters it ranged from $3.9M (Q2 2026) to $8.8M (Q3 2025).
| Quarter | Research fees revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $3.9M | -52% | -41% |
| Q1 2026 | $8.1M | +6% | +100% |
| Q4 2025 | $7.7M | -13% | +61% |
| Q3 2025 | $8.8M | +33% | — |
| Q2 2025 | $6.6M | +63% | — |
| Q1 2025 | $4.1M | -15% | — |
| Q4 2024 | $4.8M | — | — |
Q2 2026 at a glance
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is AbCellera Biologics' Research fees revenue?
AbCellera Biologics' Research fees revenue was $3.9M in Q2 2026 (second quarter 2026), -52% from Q1 2026.
How has AbCellera Biologics' Research fees revenue changed?
Over the last 7 quarters it ranged from $3.9M (Q2 2026) to $8.8M (Q3 2025).